Proactiveinvestors is a leading multimedia news organization, investor portal and events management business with offices in New York, Sydney, Toronto and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of... More
Regenicin (OTCBB:RGIN) said Tuesday it has reimbursed Lonza Walkersville Inc., a supplier to the biopharmaceuticals market, $0.26 million for the work Lonza did in moving its main product candidate through the FDA application process.
In late April, New Jersey-based Regenicin, which specializes in the development of regenerative cell therapies to restore damaged tissues and organs, received a letter from Lonza alleging the company was in breach of their "know-how license and stock purchase agreement". The letter noted a past due payment of $183,687, which was later increased to $260,344 in June.
Regenicin said that while there was a dispute relating to the amount owed, the company paid the invoice in full to avoid a conflict with what it called "an important contractual partner".
"We look forward to a long and successful relationship in the future with the Lonza team," said Regenicin CEO Randall McCoy, "and we're happy to have this issue behind us as we move forward."
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha
community. Instablog posts are not selected, edited or screened by Seeking Alpha editors,
in contrast to contributors' articles.
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
Regenicin reimburses Lonza Walkersville in full 0 comments
Regenicin (OTCBB:RGIN) said Tuesday it has reimbursed Lonza Walkersville Inc., a supplier to the biopharmaceuticals market, $0.26 million for the work Lonza did in moving its main product candidate through the FDA application process.
In late April, New Jersey-based Regenicin, which specializes in the development of regenerative cell therapies to restore damaged tissues and organs, received a letter from Lonza alleging the company was in breach of their "know-how license and stock purchase agreement". The letter noted a past due payment of $183,687, which was later increased to $260,344 in June.
Regenicin said that while there was a dispute relating to the amount owed, the company paid the invoice in full to avoid a conflict with what it called "an important contractual partner".
"We look forward to a long and successful relationship in the future with the Lonza team," said Regenicin CEO Randall McCoy, "and we're happy to have this issue behind us as we move forward."
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
Share this Instablog
Latest Followers
Latest Comments
Most Commented
Posts by Themes